Physician profile
Joshua May
NPI 1205037553
$3,537.20
in general payments reported to CMS, 2019-2025
21 companies · $555 in 2025
The $555 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $269 · 2020: $15.93 · 2021: $189 · 2022: $395 · 2023: $1,104 · 2024: $1,010 · 2025: $555.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,669.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,668.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $833.98 | 2019-2025 | Trintellix |
| Abbvie INC. | $632.24 | 2021-2025 | |
| Corium, LLC | $530.99 | 2022-2025 | Azstarys |
| Lundbeck LLC | $362.78 | 2019-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $251.74 | 2022-2024 | Qelbree, Qelbree |
| Merck Sharp & Dohme LLC | $178.71 | 2019-2023 | Belsomra |
| Teva Pharmaceuticals USA, INC. | $145.87 | 2023-2025 | Austedo Xr, Austedo Xr |
| Janssen Pharmaceuticals, INC | $134.07 | 2019-2023 | Spravato |
| Axsome Therapeutics, INC. | $92.48 | 2024-2025 | Auvelity |
| Bausch Health US, LLC | $54.61 | 2019-2023 | Wellbutrin, Aplenzin |
| Otsuka America Pharmaceutical, INC. | $52.75 | 2023-2025 | Rexulti |
| Tris Pharma INC | $51.26 | 2022-2024 | Dyanavel Xr |
| Eisai INC. | $38.00 | 2021-2022 | |
| Boston Scientific Corporation | $34.49 | 2022 | |
| Neos Therapeutics, LP | $33.13 | 2024 | Adzenys Xr-Odt |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $24.32 | 2023 | Quviviq |
| Vanda Pharmaceuticals INC. | $20.32 | 2025 | Fanapt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.96 | 2025 | Caplyta |
| Adlon Therapeutics L.P. | $17.62 | 2021 | |
| Shire North American Group INC | $15.06 | 2019 | |
| Almatica Pharma LLC | $12.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua May listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.